Mixed Disulfide Thienopyridine Conjugates for Predictable Antiplatelet Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Thienopyridine compounds used as antiplatelet agents, such as clopidogrel, ticlopidine, and prasugrel, require oxidative bioactivation by polymorphic cytochrome P450 enzymes, leading to inconsistent dosing, toxicity, and adverse effects like neutropenia and excessive bleeding due to the production of reactive metabolites.
Innovation Solution
Development of mixed disulfide conjugates of thienopyridine compounds that produce active metabolites in the presence of endogenous glutathione without the need for P450-mediated bioactivation, bypassing the oxidative bioactivation process and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thienopyridine compounds are used as prodrugs requiring P450-mediated oxidative bioactivation, then antiplatelet activity is achieved, but dosing consistency deteriorates and toxicity increases
Solution Approach 1:
The patent extracts the bioactivation step from the therapeutic pathway by designing compounds that are already in their active form or can be converted to active form without P450 enzymes. This eliminates the polymorphic cytochrome P450-mediated oxidative bioactivation step entirely, achieving consistent dosing response while reducing complexity of the activation process
Solution Approach 2:
The patent changes the chemical parameter of the thienopyridine compounds by developing mixed disulfide conjugates that alter the bioactivation pathway. These conjugates are designed to be converted to active metabolites through non-P450 mechanisms, fundamentally changing how the drug becomes active and enabling predictable dosing across different patients
2Reliability
If P450-mediated oxidative bioactivation is used, then active metabolites are produced, but toxic reactive metabolites are also produced
Solution Approach 1:
The patent converts the harmful P450-mediated oxidative pathway into a beneficial non-oxidative pathway. By designing mixed disulfide conjugates that undergo cysteine conjugation instead of P450 oxidation, the process transforms what would be a harmful metabolic route into a safe and effective activation mechanism that produces active metabolites without toxic byproducts
Solution Approach 2:
The patent introduces cysteine conjugation as an intermediary pathway between the prodrug and active metabolite. This intermediary mechanism replaces the direct P450 oxidation route, allowing the drug to be activated through a safer metabolic pathway that avoids the formation of toxic reactive metabolites while still achieving the desired therapeutic effect
3Reliability
If thienopyridine prodrugs are administered, then antiplatelet effect is achieved, but onset time is delayed
Solution Approach 1:
The patent applies preliminary action by pre-configuring the drug molecules as mixed disulfide conjugates that are primed for rapid conversion to active metabolites. This preliminary structural arrangement allows the compounds to be quickly activated upon administration through cysteine conjugation, eliminating the need for slow P450-mediated oxidation and achieving rapid onset of antiplatelet effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mixed disulfide conjugates provide predictable dosing, reduced toxicity, and rapid therapeutic onset, with active metabolites released within 30 minutes, improving treatment efficacy for cardiovascular events and enhancing stability for research use.
Implementation Method 1
the mixed disulfide conjugates of thienopyridine compounds of the present invention are capable of producing active thienopyridine metabolites (e.g., active thienopyridine metabolites capable of antiplatelet activity) in the presence of endogenous glutathione (GSH) without the need for bioactivation by P450s
Data Source
Figure 1
Figure 2A~2D
Figure 3
AI summary
This invention is in the field of medicinal chemistry. In particular, the invention relates to mixed disulfide conjugates of thienopyridine compounds, and their use as therapeutics for the treatment, amelioration, and prevention of cardiovascular diseases.